Literature DB >> 3831022

The pathogenesis of eosinophilic endomyocardial disease in patients with carcinomas of the lung.

C J Spry, A P Weetman, I Olsson, P C Tai, E G Olsen.   

Abstract

Studies were done on a patient with a carcinoma of the lung induced by hypereosinophilia who was thought to be at risk from developing eosinophilic endomyocardial disease to see whether the development of heart disease could be related to abnormalities in the morphology or kinetics of blood eosinophils. The patient was a 61-year-old man who had a partial resection of a squamous cell bronchial carcinoma of anaplastic large cell type which has spread locally. Seven months later, he developed a blood eosinophil count of 33.9 x 10(9)/1. There were only transient responses to treatment with steroids and tumor irradiation, and he died 15 weeks later. Up to 3 x 10(9)/1 blood eosinophils were degranulated, correlating with serum levels of eosinophil cationic protein. The blood half-life of 111indium-labeled eosinophils was prolonged to 53 h, but their distribution was normal. Although an unsuccessful search was made during life for the development of endomyocardial damage, at postmortem the left ventricle had features of eosinophilic endomyocardial disease in the acute necrotic stage. Among 13 other reported patients with carcinoma of the lung and hypereosinophilia, three also had endomyocardial disease or myocardial lesions. These findings confirm the suggestion that the presence in the blood of greater than 1 x 10(9)/1 degranulated eosinophils can be used to predict the development of eosinophilic endomyocardial disease before it becomes apparent clinically, and they also add weight to the hypothesis that blood eosinophil degranulation causes this complication of hypereosinophilic states.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3831022     DOI: 10.1007/bf02066412

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  47 in total

1.  Altered tissue eosinophils in Hodgkin's Disease.

Authors:  R T Parmley; S S Spicer
Journal:  Exp Mol Pathol       Date:  1975-08       Impact factor: 3.362

2.  Unusual leukocyte responses in primary carcinoma of the lung.

Authors:  R J FAHEY
Journal:  Cancer       Date:  1951-09       Impact factor: 6.860

3.  [Eosinophilia associated with malignant tumors of the bronchus and stomach].

Authors:  G Manelis; D Aderka
Journal:  Harefuah       Date:  1976-03-01

4.  Letter: Eosinophilia in bronchogenic carcinoma.

Authors:  T M Healy
Journal:  N Engl J Med       Date:  1974-10-10       Impact factor: 91.245

5.  [Hypereosinophilic syndrome with Löffler's endocarditis in Hodgkin's disease (author's transl)].

Authors:  G Keiser; J R Rüttner; H Wacker; O Meienberg; A Luz
Journal:  Dtsch Med Wochenschr       Date:  1974-09-13       Impact factor: 0.628

6.  Changes in the carbohydrate metabolism of mitogenically stimulated human peripheral lymphocytes. I. Stimulation by phytohaemagglutinin.

Authors:  D Roos; J A Loos
Journal:  Biochim Biophys Acta       Date:  1970-12-29

7.  Activation of antibody-dependent cell-mediated cytotoxicity of human neutrophils and eosinophils by separate colony-stimulating factors.

Authors:  M A Vadas; N A Nicola; D Metcalf
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

8.  Eosinophilia associated with metastatic carcinoma.

Authors:  L R Sataline; E Mobley
Journal:  Ohio State Med J       Date:  1967-11

9.  Red cell and plasma volumes in normal adults.

Authors:  P J Hurley
Journal:  J Nucl Med       Date:  1975-01       Impact factor: 10.057

10.  Kinetic studies of a tumor-induced leukemoid reaction in mice.

Authors:  D R Boggs; E Malloy; S S Boggs; P A Chervenick; R E Lee
Journal:  J Lab Clin Med       Date:  1977-01
View more
  4 in total

Review 1.  Eosinophils. Assays and interpretation.

Authors:  D E Maddox
Journal:  Clin Rev Allergy       Date:  1988

Review 2.  Eosinophils in eosinophilic endomyocardial disease.

Authors:  C J Spry
Journal:  Postgrad Med J       Date:  1986-06       Impact factor: 2.401

3.  Recombinant human interleukin 5 is a selective activator of human eosinophil function.

Authors:  A F Lopez; C J Sanderson; J R Gamble; H D Campbell; I G Young; M A Vadas
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

4.  Tumor-associated eosinophilia in a patient with EGFR-positive, MET-amplified lung adenocarcinoma refractory to targeted therapy: a case report and review of literature.

Authors:  Nan Geng; Wenxia Hu; Hui Ge; Shaonan Xie; Cuimin Ding
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.